AstraZeneca, drugmakers release promising cancer data [Video]

Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.

Good morning! I’m back in New York City after spending the last weekend in Chicago for the American Society of Clinical Oncology annual meeting.

More than 5,000 research abstracts were presented or published at ASCO. They included data on existing drugs, experimental treatments, AI tools and ideas for improving patient care. 

Here are some data highlights and executive commentary from the larger companies I follow: 

AstraZeneca wins big: 

• The company’s second-best-selling drug, Tagrisso, reduced the risk of disease progression or death by 84% compared to placebo in patients with stage three non-small cell lung cancer caused by mutations in a gene called EGFR, according to new late-stage trial results. The treatment kept the disease under control for a median of over three years – or 39 months – while patients who received a placebo had a median progression-free survival of around five months.
• Dave …